How can today’s CDMOs ensure they can meet tomorrow's demands?

8 0

1 0

Dr. Mimoun Ayoub, Ph.D., Senior VP, Global Head of Sales & Key Account Management, discusses our broad CDMO capabilities to supply complex modalities such as small to large-scale peptides (including GLP-1s), lipids and oligos, as well as Lipid NanoParticle (LNP) formulation, sterile injectable drug products, and our extensive capacity of small molecule APIs & Drug Products, both highly potent and regular potency for Oral Solid Dosage.

1 0

It was great talking to Dr Himanshu Gadgil, CEO at Enzene Biosciences at BIO International Convention about the recent launch of Enzene's Discvery Services Division and much more.

9 0

Brittany L. Hayes, Ph.D. speaks at DCAT 2024 about Corden Pharma Highly Potent & Oncology Platform Highlights, focused on 3 main areas:

In the past year Corden Pharma launched their Drug Product Innovation Centre of Excellence at our CordenPharma Plankstadt (DE) facility, where they added bioavailability technologies like Hot Melt Extrusion (HME), spray drying, nanomilling and micronization. In addition, they have capabilities to take gram quantities of APIs to make small-scale prototypes for tablets or capsules, and using our Accelerated Stability Assessment Program, quickly identify and predict stability to bring your project rapidly into First-in-Human (FIH).

Secondly, they anticipate the opening of our new clinical trial area in Plankstadt, where they have the capacity to produce 5-60 Kilo batches of tablets and capsules using technologies such as wet and dry granulation, compression coating, and a state-of-the-art encapsulator with filling modules for direct API into individually weighed capsules, as well as powders, granules, pellets, and minitablets.

Lastly, in conjunction with their bioavailability enhancement technologies for non-GMP and long track record of experience with complex formulations, they are expanding into the oral solid dosage formulation of peptides. This exciting area provides oral ingestion of peptides via capsules or tablets, which offers definite advantages over traditional auto-injectors for your patients.

0 0

1 0

Matthieu Giraud, PhD speaks at DCAT 2024 on our Lipids & Carbohydrates Platform Highlights.

The highlights of our Lipids & Carbohydrates platform center firstly on the launch of our Lipid NanoParticle (LNP) Starter Kits. The kits include the most important lipids targeted for proper LNP formulation, which are compatible with most LNP equipment traditionally found in development centers. Drawing upon decades of specialized lipid manufacturing, CordenPharma provides very high-quality lipids for the kits, which are equivalent with commercial-grade materials, ensuring the quality is the same from R&D up to clinical phases.
In addition, we introduced some important lipid transfection boosters such as β-Sitosterol, in order to move LNP formulation to the next level.
Lastly, since targeting has become a very important modality, we identified different lipid compositions that allow effective targeting of specific organs, as well as different ways to do coating of LNPs (e.g. either with peptides, ADCs, or carbohydrates with GalNAc). To enhance this service, we announced a partnership with pHLIP to collaborate in developing and commercializing the pHLIP-LNP targeted delivery platform for RNA-based and genetic therapeutics.

0 0

At CPHI North America we had the pleasure of catching up with the lovely Noelle Ross, Senior Business Development Manager at SGS. To learn more about the company and their expertise, watch this interview to hear what Noelle had to say.

0 0